Player grades for the Oklahoma City Thunder's 125-107 Game 2 win over the Los Angeles Lakers.

UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...

UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...

Shake Shack Inc. remains resilient, sustaining double-digit revenue growth despite inflation and cost pressures in Q1 2026.

Q2 2026 Earnings Call May 8, 2026 8:30 AM EDTCompany ParticipantsClay Whitson - Chief Strategy Officer & DirectorGregory ...

A collection of articles, podcasts & tweets from around the web to keep you in touch with the Commanders, the NFC East, the ...

Despite acquiring James Harden for clutch moments, the Cavs continue to falter in late-game situations in the playoffs.

Frank Stokes reported, "Net cash used in operating activities was $22.1 million for 1Q26," referencing annual cash bonus payments and healthcare benefits that are not expected to recur in subsequent ...

Total Orders -- Grew 3% year over year, with repeat orders outperforming total growth. Average Order Value -- $2,131, an ...

UCB to buy clinical-stage biotech company, Candid Therapeuticsfor US$ 2.2 billion: Brussels, Belgium Tuesday, May 5, 2026, 09:00 Hrs [IST] UCB, a global biopharmaceutical company, ...

Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin® Gel net revenues of $75.1 million, an increase ...